# The Drugs That Are Not Here Yet

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/the-drugs-that-are-not-here-yet

> Four investigational molecules have published human results. The most striking figure among them, 8% of body weight in four weeks, comes from the earliest and smallest study of the four.

## Key points

- CT-388's −8.0% took 4 weeks. Bofanglutide's −16.69% took 30. Rate ranks by trial length.
- A GIP agonist ALONE lost weight with NO delay in gastric emptying, so the nausea may be separable.
- But its glucose effect was transient and gone by day 29.
- Bofanglutide is called 'generally well tolerated', yet 98.9% had an adverse event.
- Bofanglutide is built for biweekly dosing, a planned version of the spacing some people improvise.
- All four are unapproved. Each will reach peptide sellers before a pharmacy.

Four molecules in development have published human results, and the most striking number among them, **8% of body weight in four weeks**, comes from the earliest and smallest study of the four.[4] That is not a coincidence. Ranking these drugs by their headline figures ranks them by how short their trials were, and every one of them will reach peptide sellers before it reaches a pharmacy.

## What has been published

*Human weight results for four investigational agents, with the trial stage and length that produced them.*

| Drug | Stage | Weight change | Over |
| --- | --- | --- | --- |
| Aleniglipron (oral)[1] | Phase 2b, 230 people | −11.3% vs placebo at 120 mg | 36 weeks |
| Bofanglutide (biweekly)[2] | Phase 2b, 340 people | −9.75% to −16.69% vs −1.15% placebo | 30 weeks |
| CT-388[4] | **Phase 1**, people with overweight or obesity | −4.7% to −8.0% vs −0.5% placebo | **4 weeks** |
| LY3537021 (GIP alone)[3] | **Phase 1**, 85 people | 3.14 kg vs 0.36 kg placebo at 25 mg | 57 days |

> **Read the last column before the third.** Weight loss on these drugs is front-loaded: steepest early, flattening as it goes. A four-week figure is measured entirely on the steep part. Nothing in this table can be projected forward, and comparing across rows compares trial durations as much as molecules. The same goes for [VK2735, a dual agonist that reported 14.7% in thirteen weeks](https://glpwatchdog.org/research/another-molecule-you-cannot-buy).

## The finding worth caring about is not a weight number

LY3537021 is the least impressive drug in that table and the most interesting entry in it. It is a **GIP receptor agonist on its own**, with no GLP-1 component, which makes it an experiment on the question the whole field wants answered.

It produced dose-dependent weight loss that persisted 35 days after the last dose. And it did so with **no delay in gastric emptying** at any dose tested, and infrequent gastrointestinal side effects.

> Weight came off without the stomach being slowed down.

That matters because delayed gastric emptying is where the nausea, vomiting and constipation come from, and those are why people stop (roughly one in ten in the trials covered elsewhere on this register). If GIP produces weight loss by a route that does not involve slowing the stomach, then the side effects and the benefit may be separable, which nobody has yet demonstrated in an approved drug.

Two cautions on the same result. The weight effect is modest at these doses, 3.14 kg against 0.36 kg on placebo. And the glucose effect *did not hold*: reductions in fasting glucose were transient and were no longer significantly different from placebo by day 29. On this evidence GIP alone looks like a weight drug rather than a diabetes drug, which is not what a GIP agonist was expected to be.

## The biweekly one

Bofanglutide is designed to be injected **once every two weeks**. It posted the largest weight reduction in the table, up to 16.69% at 30 weeks against 1.15% on placebo, in 340 Chinese adults.

That is the disciplined version of something people already improvise. Stretching a weekly drug to fortnightly, to make it affordable, rests on a mathematical model and two patients (see [stretching doses to save money](https://glpwatchdog.org/research/stretching-doses-to-save-money)). A molecule engineered for that interval and tested at it is a different proposition entirely. Amgen’s [MariTide](https://glpwatchdog.org/research/maritide-maridebart-cafraglutide-evidence) pushes the interval further, to monthly or less often, and is already in phase 3.

> **Its tolerability description and its tolerability numbers do not match.** The paper concludes the drug is generally well tolerated. It also reports adverse events in **98.9%** of people taking it (271 of 274) against 86.4% on placebo, with gastrointestinal events in 83.9% against 33.3%. Most were mild, and nearly everybody had one.

Two further limits on transferring that result. The trial used Chinese BMI thresholds, where overweight begins at 24 and obesity at 28 rather than the 25 and 30 used in the United States, so the population is lighter than a Western trial of the same labels. And the average participant was 33 years old.

## What this means for what appears online

Every drug above is unapproved. None has a label, an approved manufacturer, or a legal route to a pharmacy. A published phase 2 result is the strongest free marketing a gray-market seller ever receives, and the pattern is established. In August 2026 our register counted eleven sellers already offering retatrutide, which is still unapproved everywhere; the details are in [retatrutide’s phase 3 and the gray market](https://glpwatchdog.org/research/retatrutide-phase-3-and-the-gray-market).

- **Phase 1 means safety and dose-finding**, in tens of people, over weeks. It is not evidence a drug works.
- **Phase 2b means a dose has been chosen** and an effect estimated in a few hundred people. It is not evidence a drug is safe over years.
- **A short trial flatters every drug in this class.** Check the duration before the percentage.
- **Certainty gradings exist.** The BMJ synthesis of 262 trials rates the newest agents *very low to low* certainty (see [what 262 trials say together](https://glpwatchdog.org/research/what-262-trials-say-together)).

One housekeeping note: the aleniglipron paper carries a publisher correction. It changes one figure value, the 120 mg arm’s change in Figure 3b from −12.1 to −12.7, and restores panels missing from Figure 4.[5] The −11.3% placebo-adjusted result in the table above comes from the abstract and is unchanged.

## Frequently asked questions

### Which drug in development produces the most weight loss?

That cannot be answered from the published results, because the trials are different lengths. Bofanglutide reported up to 16.69% at 30 weeks and aleniglipron 11.3% at 36 weeks, while CT-388's 8.0% came over four weeks in a phase 1 study. The shortest trial produced the fastest rate.

### Can side effects be separated from the weight loss?

A phase 1 study of a GIP receptor agonist alone found dose-dependent weight loss with no delay in gastric emptying and infrequent gastrointestinal side effects. Since delayed gastric emptying is where the nausea comes from, that suggests the two may be separable, though the evidence comes from a very early study.

### Is a biweekly injection possible?

Bofanglutide is designed for it and was tested at that interval, reporting substantial weight loss over 30 weeks in a phase 2b trial. That is different from stretching a weekly drug to fortnightly, which rests on a mathematical model and two patients.

### Are any of these available?

No. All four are investigational, with no approval in any country, no label and no legal route to a pharmacy. Anything sold online under these names has no verified identity, purity or concentration.

### Why does trial length matter so much?

Because weight loss in this class is front-loaded, steepest in the early months and flattening afterward. A four-week result is measured entirely on the steep part of the curve and cannot be projected forward.

## References

1. Rosenstock J, Lingvay I, Ryan D, et al. Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial. Nature Medicine. 2026. PMID: 42249138. https://pubmed.ncbi.nlm.nih.gov/42249138/
2. Ji L, Gao L, Tian J, et al. Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial. Signal Transduction and Targeted Therapy. 2026. PMID: 41760612. https://pubmed.ncbi.nlm.nih.gov/41760612/
3. Roell W, Alsina-Fernandez J, Qu H, et al. Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies. Molecular Metabolism. 2026. PMID: 41391569. https://pubmed.ncbi.nlm.nih.gov/41391569/
4. Chakravarthy MV, Rodriguez R, Hergarden A, et al. Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity. Molecular Metabolism. 2026. PMID: 41319798. https://pubmed.ncbi.nlm.nih.gov/41319798/
5. Rosenstock J, Lingvay I, Ryan D, et al. Publisher Correction: Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial. Nature Medicine. 2026. PMID: 42343118. https://pubmed.ncbi.nlm.nih.gov/42343118/

---

Cite as: GLP Watchdog, Nora Bissett, "The Drugs That Are Not Here Yet", published 2026-08-20, updated 2026-10-30. https://glpwatchdog.org/research/the-drugs-that-are-not-here-yet

Canonical HTML page: https://glpwatchdog.org/research/the-drugs-that-are-not-here-yet

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
